<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39404765</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7755</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</Title><ISOAbbreviation>Cancer Epidemiol Biomarkers Prev</ISOAbbreviation></Journal><ArticleTitle>Changes in Breast Cancer Screening Prevalence in the US During the COVID-19 Pandemic, 2018-2022.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1158/1055-9965.EPI-24-0540</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Annual mammography screening declined year-on-year during the COVID-19 pandemic through 2021. This study examined changes in 2022 compared to 2018 in the national prevalence of self-reported up-to-date mammography.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using 2018-2022 data from the Center for Disease Control and Prevention's (CDC) Behavioral Risk Factor Surveillance System (BRFSS), we assess relative changes defined as annual prevalence ratios (aPR) in the SR receipt of past-year and up-to-date (UTD) breast cancer screening (bi-annual mammography in women ages 50-74 years) during the third year of the COVID-19 pandemic overall and by sociodemographic characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">UTD BC screening declined for the first time since 2018 (2018 compared to 2022, from 78.7% to 76.6%; aPR, 0.97; 95% CI, 0.96-0.98), despite a small increase in past-year breast cancer screening from 2020 and 2022 (57.9% to 59.6%; aPR, 1.03; 95% CI, 1.01-1.05). This translated to 747,791 fewer women reporting UTD with recommended BC screening in 2022 vs. 2018. UTD BC screening declines between 2018-2022 were largest for American Indian/Alaska Native women (74.8% to 62.2%; aPR, 0.83; 95% CI, 0.74-0.93), women with less formal educational attainment (&lt; high school: 73.1% to 65.5%; aPR, 0.9; 95% CI, 0.85-0.95), and women without a usual source of care (48% to 42.9%; aPR, 0.85; 95% CI, 0.78-0.92).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Previously noted pandemic-related declines in past-year BC screening now reflect in women reporting being UTD, with the largest declines in AI/AN and lower SES women.</AbstractText><AbstractText Label="IMPACT" NlmCategory="CONCLUSIONS">Future studies should monitor screening prevalence in relation to BC diagnostic stage, overall and by sociodemographic groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ashad-Bishop</LastName><ForeName>Kilan C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0001-6846-3499</Identifier><AffiliationInfo><Affiliation>University of Miami Rosenstiel School of Marine, Atmospheric, and Earth Science, Miami, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Star</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3522-9609</Identifier><AffiliationInfo><Affiliation>American Cancer Society, Kennesaw, Georgia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giaquinto</LastName><ForeName>Angela N</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0003-2548-9693</Identifier><AffiliationInfo><Affiliation>American Cancer Society, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-3344-2238</Identifier><AffiliationInfo><Affiliation>American Cancer Society, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jemal</LastName><ForeName>Ahmedin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0000-4111</Identifier><AffiliationInfo><Affiliation>American Cancer Society, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandi</LastName><ForeName>Priti</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1169-4231</Identifier><AffiliationInfo><Affiliation>American Cancer Society, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Epidemiol Biomarkers Prev</MedlineTA><NlmUniqueID>9200608</NlmUniqueID><ISSNLinking>1055-9965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39404765</ArticleId><ArticleId IdType="doi">10.1158/1055-9965.EPI-24-0540</ArticleId><ArticleId IdType="pii">749099</ArticleId></ArticleIdList></PubmedData></PubmedArticle>